HCELL

HCell is working diligently to get ready to conduct the clinical study for this significant, yet unmet, medical need for Alopecia Areata in pediatric patients with HC017AA​ and Androgenic Alopecia with HC0100... HCell is ramping up continued research, business operations, and sales and marketing. An experienced management team will swiftly navigate the company through any obstacles and challenges standing in the way of reaching our $1.13 billion revenue estimates by the end of year five in full-scale operation.​... HCell Inc., a privately held biotechnology company based in Austin, Texas, focusing on Alopecia Areata in the Pediatric Population, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with alopecia areata, a devastating hair loss disease.

Also known as: HCell Inc.